A Study in Healthy Adults Investigating Eptinezumab Produced by 2 Different Manufacturing Cell Lines
Public ClinicalTrials.gov record NCT05074459. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Interventional, Randomized, Double-blind, Parallel-group, Healthy Subject, Single Dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Eptinezumab Manufactured Using Two Different Cell Lines
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Eptinezumab is a preventive treatment for migraine. The drug is made from a process that currently uses yeast cells for production of the drug. The trial researchers want to test whether using a new production cell line to make eptinezumab will affect the way the drug behaves in the body. To do this, the researchers will give a single dose of eptinezumab to healthy participants. Some of the participants will get eptinezumab that has been made from yeast cells. Others will get eptinezumab made with the new cell line.
Study identification
- NCT ID
- NCT05074459
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 84 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 26, 2021
- Primary completion
- Jul 17, 2022
- Completion
- Jul 17, 2022
- Last update posted
- Aug 28, 2022
2021 – 2022
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Labcorp Clinical Research Unit, Inc. | Daytona Beach | Florida | 32117 | — |
| Labcorp Clinical Research Unit, Inc. | Madison | Wisconsin | 53715 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Healthy Participants trials
Other public records listing Healthy Participants. Sorted by last update posted; newest first. Not a recommendation.
- NCT07780383: A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration Not yet recruiting
- NCT07219719: Temporal Interference for Thalamocortical Activity and Network Modulation Recruiting
- NCT07753252: Phase 1 Study in Healthy Adults to See How Sevabertinib Changes Metformin Levels in the Body Not yet recruiting
- NCT07746167: Pupillary Dilation Reflex in Healthy Volunteers Recruiting
- NCT07745907: A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese Volunteers Recruiting
- NCT01060371: Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05074459, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 28, 2022 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05074459 live on ClinicalTrials.gov.